This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swanson, R. A. Articles by Sharp, F. R. Search for Related Content PubMed PubMed Citation Articles by Swanson, R. A. Articles by Sharp, F. R.

Stroke, Vol 21, 322-327, Copyright © 1990 by American Heart Association

ARTICLES

Methionine sulfoximine reduces cortical infarct size in rats after middle cerebral artery occlusion

RA Swanson, K Shiraishi, MT Morton and FR Sharp
Neurology Service, Veterans Affairs Medical Center, San Francisco 94121.

The methionine analogue methionine sulfoximine was administered to 10 rats 24 hours before occlusion of the proximal left middle cerebral artery. Three days later the rats were decapitated and the brain infarct volumes were compared with those in 10 control rats that received saline before middle cerebral artery occlusion. The mean volume of the infarct in the cerebral cortex was reduced by 33% in the group treated with methionine sulfoximine (p less than 0.01). This protective effect may be mediated by a presynaptic mechanism; methionine sulfoximine profoundly inhibits brain glutamine synthetase, thereby interrupting the astrocyte-neuron glutamate shuttle and impairing neuronal glutamate release. Methionine sulfoximine also increases brain glycogen stores, and this increased energy reserve may benefit penumbral tissue during the peri-infarct period. Further study of the mechanisms by which methionine sulfoximine decreases infarct volume could lead to new therapeutic approaches for stroke.

This article has been cited by other articles:

				S. W. Suh, J. P. Bergher, C. M. Anderson, J. L. Treadway, K. Fosgerau, and R. A. Swanson Astrocyte Glycogen Sustains Neuronal Activity during Hypoglycemia: Studies with the Glycogen Phosphorylase Inhibitor CP-316,819 ([R-R*,S*]-5-Chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide) J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 45 - 50. [Abstract] [Full Text] [PDF]

				O. B. Dimitrijevic, S. M. Stamatovic, R. F. Keep, and A. V. Andjelkovic Absence of the Chemokine Receptor CCR2 Protects Against Cerebral Ischemia/Reperfusion Injury in Mice Stroke, April 1, 2007; 38(4): 1345 - 1353. [Abstract] [Full Text] [PDF]

				J. Luo, H. Chen, D. B. Kintner, G. E. Shull, and D. Sun Decreased Neuronal Death in Na+/H+ Exchanger Isoform 1-Null Mice after In Vitro and In Vivo Ischemia J. Neurosci., December 7, 2005; 25(49): 11256 - 11268. [Abstract] [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, R. L. Zhang, M. Lu, J. Adams, P. J. Elliott, and M. Chopp Postischemic (6-Hour) Treatment With Recombinant Human Tissue Plasminogen Activator and Proteasome Inhibitor PS-519 Reduces Infarction in a Rat Model of Embolic Focal Cerebral Ischemia Stroke, December 1, 2001; 32(12): 2926 - 2931. [Abstract] [Full Text] [PDF]

				H. Yanamoto, I. Nagata, Y. Niitsu, Z. Zhang, J.-H. Xue, N. Sakai, H. Kikuchi, and C. Iadecola Prolonged Mild Hypothermia Therapy Protects the Brain Against Permanent Focal Ischemia Editorial Comment Stroke, January 1, 2001; 32(1): 232 - 239. [Abstract] [Full Text] [PDF]